Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jun 1;158(6):1560-1563.
doi: 10.1210/en.2017-00252.

Incretin-Based Therapies: Revisiting Their Mode of Action

Affiliations
Comment

Incretin-Based Therapies: Revisiting Their Mode of Action

Brian T Layden et al. Endocrinology. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
GPCR signaling events that may be differentially contributing to aspects of β-cell function and proliferation. (1) GPCR activation leads to Gα downstream signaling effects that mediate aspects of β-cell function and proliferation. (2) Gβγ may also influence β-cell function and proliferation. (3) Evidence suggests that β-arrestin (β-Ar) mediates β-cell function/proliferation. (4) When GPCRs are activated, each receptor (R) is internalized, recycled, or degraded at differential rates. (5) GPCRs can form dimers (homodimers or heterodimers) in which each of these five steps can influence receptor signaling abilities. (A) Receptor internalization can result in rapid return to the plasma membrane or a more profound downregulation, influencing the GPCR’s signaling abilities. (B) β-arrestin, which contributes to the downregulation process, also can activate pathways such as ERK. Zhu et al. (19)demonstrated the importance of β-arrestin in β-cell function. (C) Gα proteins, in particular Gsα, Gq/11α, or Gi/oα, and downstream signals, influencing β-cell function. Multiple other G-protein modulators influence the inactivation of Gα proteins. (D) Gβγ can influence ion channel function, mitogen-activated protein kinases activation, and adenylate cyclase properties, among others.

Comment on

References

    1. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol. 1902;28(5):325–353. - PMC - PubMed
    1. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082. - PubMed
    1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52. - PubMed
    1. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203–216. - PMC - PubMed
    1. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12(10):566–592. - PubMed

Publication types